Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Authors:
- Stephanie L. WethingtonSWStephanie L. Wethington
- Payal D. ShahPSPayal D. Shah
- Lainie MartinLMLainie Martin
- Janos L. TanyiJTJanos L. Tanyi
- Nawar LatifNLNawar Latif
- Mark MorganMMMark Morgan
- Drew A. TorigianDTDrew A. Torigian
- Diego RodriguezDRDiego Rodriguez
- Simon A. SmithSSSimon A. Smith
- Emma DeanEDEmma Dean
- Susan M. DomchekSDSusan M. Domchek
- Ronny DrapkinRonny Drapkin
Open Access
- 16 September 2024
- other
- Published by American Association for Cancer Research (AACR)